Cutaneous Plasmacytosis treated with Tocilizumab: A Case Report and Review of the Literature

Conclusions: Cutaneous and systemic plasmacytosis can affect both children and adults and presently lacks consensus statements on definitive treatment regimens. A continued consolidation of the little knowledge we have about this disease is needed, in order to uncover possible patterns of treatment efficacy, and to maintain awareness of this unusual disease in a dermatologist’s differential diagnoses.

[1]  Soo-Chan Kim,et al.  Isolated Benign Primary Cutaneous Plasmacytosis in a Child , 2014, Pediatric dermatology.

[2]  A. Sohani,et al.  Diagnosis and management of Castleman disease. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[3]  M. Fung,et al.  Cutaneous Plasmacytosis with Perineural Involvement , 2014, Case reports in dermatological medicine.

[4]  L. Cerroni,et al.  Cutaneous plasmacytosis: report of 6 cases with or without systemic involvement. , 2013, Journal of the American Academy of Dermatology.

[5]  J. Chan,et al.  Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. , 2012, Seminars in diagnostic pathology.

[6]  Jian-Fang Sun,et al.  Cutaneous and systemic plasmacytosis showing histopathologic features as mixed-type Castleman disease: a case report. , 2012, The American Journal of dermatopathology.

[7]  Xiang Mei,et al.  A case of cutaneous plasmacytosis , 2012, Experimental and therapeutic medicine.

[8]  Robert E. Brown,et al.  Cutaneous and systemic plasmacytosis vs. cutaneous plasmacytic castleman disease: review and speculations about pathogenesis. , 2011, Clinical lymphoma, myeloma & leukemia.

[9]  L. Chularojanamontri,et al.  Cutaneous plasmacytosis: a case report and review of pulmonary findings , 2011, Dermatology reports.

[10]  J. van Lunzen,et al.  Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. , 2011, Blood.

[11]  M. Shin,et al.  Case of isolated benign primary cutaneous plasmacytosis in a child , 2011, The Journal of dermatology.

[12]  B. Leber,et al.  Mixed variant multicentric Castleman disease treated with rituximab: case report. , 2010, Journal of pediatric hematology/oncology.

[13]  R. Bhatnagar,et al.  Isolated benign primary cutaneous plasmacytosis in children: two illustrative cases. , 2009, Archives of dermatology.

[14]  S. Montoto,et al.  Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease , 2007, Annals of Internal Medicine.

[15]  Philip R. Cohen,et al.  Cutaneous castleman's disease responds to anti–interleukin-6 treatment , 2007, Molecular Cancer Therapeutics.

[16]  S. Meehan,et al.  Cutaneous and systemic plasmacytosis. , 2007, Journal of the American Academy of Dermatology.

[17]  M. Landthaler,et al.  Targeting T Cells to Hit B Cells: Successful Treatment of Cutaneous Plasmacytosis with Topical Pimecrolimus , 2006, Dermatology.

[18]  A. Jayaraman,et al.  Cutaneous Plasmacytosis: A Report of Five Cases with Immunohistochemical Evaluation for HHV-8 Expression , 2006, The American Journal of dermatopathology.

[19]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[20]  K. Yoshikawa,et al.  Treatment of facial lesion of cutaneous plasmacytosis with tacrolimus ointment. , 2003, Journal of the American Academy of Dermatology.

[21]  K. Kitamura,et al.  A CASE OF PLASMACYTOSIS WITH MULTIPLE PECULIAR ERUPTIONS , 1980, The Journal of dermatology.

[22]  H. Tseng,et al.  Primary cutaneous plasmacytosis successfully treated with topical photodynamic therapy. , 2005, Acta dermato-venereologica.

[23]  K. Nishioka,et al.  Intralesional steroid-therapy-induced reduction of plasma interleukin-6 and improvement of cutaneous plasmacytosis. , 1995, Dermatology.

[24]  T. Saida,et al.  Primary cutaneous plasmacytosis: report of three cases and review of the literature. , 1994, Dermatology.